GSK plc Reports Transaction in Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jul 24, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, 6-k, foreign-private-issuer
TL;DR
GSK bought/sold its own shares, filing a 6-K on 7/24/25.
AI Summary
GSK plc announced on July 24, 2025, that it has completed a transaction involving its own shares. The filing, a Form 6-K, indicates this is a report of a foreign private issuer for the month of July 2025. The company's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Why It Matters
This filing informs investors about GSK's activities related to its own stock, which can impact share count and potentially influence stock price.
Risk Assessment
Risk Level: low — This is a routine filing reporting a transaction in the company's own shares, not a significant event like an acquisition or earnings miss.
Key Players & Entities
- GSK plc (company) — Registrant
- 001-15170 (dollar_amount) — Commission File Number
- 79 New Oxford Street, London, WC1A 1DG (company) — Principal executive office address
- 20250724 (date) — Filing date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the primary subject of this filing?
The filing reports a 'Transaction in own shares' by GSK plc.
When was this filing made?
The filing was made on July 24, 2025.
Where is GSK plc's principal executive office located?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 24, 2025 regarding GSK plc (GLAXF).